Open Access<p>Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA <em>MEG3</em> Enhances Gene Therapy in Castration-Resistant Prostate Cancer</p>
Author(s) -
Zongguang Tai,
Jinyuan Ma,
Jingjin Ding,
Huijun Pan,
Rongrong Chai,
Congcong Zhu,
Zhen Cui,
Zhongjian Chen,
Quangang Zhu
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s282107
Subject(s) - in vivo , prostate cancer , aptamer , cancer research , genetic enhancement , gene delivery , in vitro , endocytosis , chemistry , cancer , microbiology and biotechnology , biology , medicine , cell , gene , biochemistry
The clinical management of patients with castration-resistant prostate cancer (CRPC) is difficult. However, novel treatment methods are gradually being introduced. Considering the adverse effects of traditional treatments, recent studies have investigated gene therapy as a method to combat CRPC; but, the application of long non-coding (lnc) RNA in gene therapy remains scarce, despite their promise. Therefore, it is imperative to develop a system that can efficiently deliver lncRNA for the treatment of CRPC. Here, we investigated the efficacy of a delivery system by introducing the plasmid-encoding tumor suppressor lncRNA MEG3 (pMEG3) in CRPC cells.